• Monday, Dec 06, 2021
  • Last Update : 06:13 pm

US FDA advisers back Pfizer/BioNTech Covid-19 vaccine for children

  • Published at 11:58 am October 27th, 2021
A healthcare worker prepares a Pfizer Covid-19 vaccination in Los Angeles, California, US, January 7, 2021 Reuters

The vaccine showed 90.7% efficacy in a clinical trial of children aged five  to 11, say the companies

An expert panel on Tuesday voted overwhelmingly to recommend the US Food and Drug Administration (FDA) authorize the Pfizer Inc and BioNTech SE Covid-19 vaccine for children ages five to 11, saying the benefits of the shot outweigh the risks.

An authorization for that age group would be would be an important regulatory step toward reaching about 28 million children for inoculation, most of them back in school for in-person learning.

The vaccine could be available to the younger age group as soon as next week. The FDA is not obligated to follow the advice of its outside experts, but usually does. The vote was 17 in favor with one abstention.

If the FDA authorizes the shots for this age group, an advisory panel to the US Centers for Disease Control and Prevention will meet next week to make a recommendation on the administration of the vaccine. The CDC director will make the final call.

While children becoming seriously ill or dying from Covid-19 is relatively rare compared with adults, some develop complications, and infections in unvaccinated kids have risen due to the easily transmitted Delta variant of the coronavirus. 

Data from the American Academy of Pediatrics shows that more than 500 US children have died from Covid-19.

It "is the eighth highest killer of kids in this age group over the past year," said Dr Amanda Cohn, a pediatric vaccine expert at the CDC and a voting member of the panel. "Use of this vaccine will prevent deaths, will prevent ICU admissions and will prevent significant long-term adverse outcomes in children."

Also Read - Pfizer/BioNTech Covid jabs show 90.7% efficacy in trial in children

Only a few other countries, including China, Cuba and the United Arab Emirates, have so far cleared Covid-19 vaccines for children in this age group and younger.

In the United States, just 57% of the population is fully vaccinated, lagging other nations such as the UK and France.

Still, the percentage of young children who receive the shots may be low. The US vaccination rate for 12 to15 year olds trails other age groups at roughly 47%.

The World Health Organization since May has been urging rich countries to reconsider plans to vaccinate children and instead donate Covid-19 shots to the Covax program for distribution to poorer countries.

Lower dose

Pfizer and BioNTech are seeking clearance for a lower, 10-microgram dose of the vaccine in young children, versus 30 micrograms for those age 12 and older. 

The shot has been authorized for ages 12-15 since May after being cleared for those age 16 and older in December.

The companies have said their vaccine showed 90.7% efficacy against the coronavirus in a clinical trial of children aged five to 11.   

The advisers paid close attention to the rate of a heart inflammation called myocarditis that has been linked to both the Pfizer/BioNTech and Moderna (MRNA.O) vaccines, particularly in young men.

Also Read - Moderna says its Covid-19 vaccine protective, safe in young children

If the number of myocarditis cases in the younger age group turns out to be similar to that in 12 to 15 year olds, the hospitalizations prevented for Covid-19 would outnumber those prevented for myocarditis in most scenarios analyzed, FDA staff reviewers said in documents prepared ahead of Tuesday's meeting.

Some panel members suggested that due to the myocarditis risk, the vaccine should be given to a narrower group of children, such as those with conditions that make them more likely to be hospitalized.

"There are certain kids that should be vaccinated. The question of how broadly to use it, I think it's a substantial one," said Eric Rubin, Editor-in-Chief of the New England Journal of Medicine.

If authorized, the Pfizer/BioNTech vaccine is likely to be the only one available to the age group in the United States for some time.

On Monday, Moderna released data from its own clinical trial of children ages six to 11, and said it would soon ask regulators for authorization in the age group.

It is unclear when US regulators will consider that. The company is still waiting for a response to its application filed in June for use of its vaccine in children ages 12 through 17.

Pfizer has said it could have data from its clinical trial in even younger children - ages two to four - by year-end.

Facebook 50
blogger sharing button blogger
buffer sharing button buffer
diaspora sharing button diaspora
digg sharing button digg
douban sharing button douban
email sharing button email
evernote sharing button evernote
flipboard sharing button flipboard
pocket sharing button getpocket
github sharing button github
gmail sharing button gmail
googlebookmarks sharing button googlebookmarks
hackernews sharing button hackernews
instapaper sharing button instapaper
line sharing button line
linkedin sharing button linkedin
livejournal sharing button livejournal
mailru sharing button mailru
medium sharing button medium
meneame sharing button meneame
messenger sharing button messenger
odnoklassniki sharing button odnoklassniki
pinterest sharing button pinterest
print sharing button print
qzone sharing button qzone
reddit sharing button reddit
refind sharing button refind
renren sharing button renren
skype sharing button skype
snapchat sharing button snapchat
surfingbird sharing button surfingbird
telegram sharing button telegram
tumblr sharing button tumblr
twitter sharing button twitter
vk sharing button vk
wechat sharing button wechat
weibo sharing button weibo
whatsapp sharing button whatsapp
wordpress sharing button wordpress
xing sharing button xing
yahoomail sharing button yahoomail